Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell and multi-omics data. We have a diverse and multi-disciplinary team, supported by world-leading scientific advisors and reputable investors.
Products, services, technology
Scailyte provides a rapid and efficient end-to-end pipeline for extracting relevant biosignatures from single-cell and multi-omics data related to efficacy, toxicity or to the mode of action of therapeutics.
Cooperation possibilities
We are partnering with biotech companies in the field of immuno-oncology that are entering Phase 1 clinical trials and want to leverage our unique capabilities in biomarker discovery and patient stratification. Reach our if you want to learn more: contact@scailyte.com
